Global Colorectal Cancer Market 2024–2033

Reports Description

As per the current market research conducted by the CMI Team, the global Colorectal Cancer Market is expected to record a CAGR of 3.4% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 22,275.3 Million. By 2033, the valuation is anticipated to reach USD 30,095.9 Million.

The colorectal cancer market encompasses a dynamic landscape of pharmaceuticals, diagnostics, and treatment services aimed at addressing the prevention, diagnosis, and management of colorectal cancer. It includes a wide array of stakeholders such as pharmaceutical companies, diagnostic laboratories, medical device manufacturers, healthcare providers, and research institutions.

Key components of the market include the development and commercialization of novel therapeutics, diagnostic tools for early detection, supportive care services, and advancements in precision medicine approaches. With rising incidence rates and advancements in medical technology, the colorectal cancer market continues to evolve, driven by innovation, research investments, and efforts to improve patient outcomes.

Colorectal Cancer Market – Significant Growth Factors

The Colorectal Cancer Market presents significant growth opportunities due to several factors:

• Advancements in Precision Medicine: The increasing understanding of molecular pathways and genetic alterations driving colorectal cancer has led to the development of targeted therapies and personalized treatment approaches, driving market growth.

• Rising Incidence Rates: The escalating incidence of colorectal cancer globally, particularly in aging populations and regions undergoing rapid urbanization and lifestyle changes, creates a larger patient pool and drives demand for screening, diagnosis, and treatment services.

• Innovations in Immunotherapy: Immunotherapy, including immune checkpoint inhibitors, has shown promising results in subsets of colorectal cancer patients, providing new treatment options and driving research and development efforts in this area.

• Technological Advancements in Diagnostic Tools: The emergence of advanced diagnostic technologies such as liquid biopsy, next-generation sequencing, and imaging modalities enhances early detection, prognostication, and treatment monitoring, driving market expansion.

• Expansion of Telemedicine Services: The integration of telemedicine into colorectal cancer care presents opportunities to improve access to specialized care, facilitate remote consultations, and enhance patient monitoring, particularly in underserved areas or during public health crises like the COVID-19 pandemic.

• Collaboration for Biomarker Discovery: Collaborative efforts between pharmaceutical companies, academic institutions, and research organizations to identify and validate novel biomarkers for colorectal cancer prognosis, treatment response prediction, and patient stratification present opportunities to advance precision medicine and develop targeted therapies.

Colorectal Cancer Market – Mergers and Acquisitions

The Colorectal Cancer Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Colorectal Cancer Market include:

• In 2023, Akeda of Japan partnered with Hutchmed of Hong Kong to secure commercial rights for the colorectal cancer drug fruquintinib outside of China. Roche is exploring the combination of Cotellic targeted therapy with immuno-oncologic agents for CRC treatment.

• In 2022, The US FDA approved the third biosimilar of the monoclonal antibody bevacizumab, known as bevacizumab-maly (Alymsys). It is indicated for subsets of patients with colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer.

• In 2021, Taiho Pharmaceutical Co., Ltd. introduced LONSURF, an anticancer drug, for colorectal cancer patients in China. The company anticipates Lonsurf to become a preferred pharmaceutical substitute for individuals with colorectal cancer, benefiting both patients and medical facilities.

These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Colorectal Cancer Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Colorectal Cancer Market – Significant Threats

The Colorectal Cancer Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

• Healthcare Access Disparities: Disparities in healthcare access, particularly in low-income and underserved communities, pose a threat to effective colorectal cancer prevention, diagnosis, and treatment. Limited access to screening programs, diagnostic tools, and specialized care may result in delayed diagnosis and poorer outcomes for patients in these populations.

• Rising Healthcare Costs: Escalating healthcare costs, including the expense of cancer treatment modalities such as chemotherapy, targeted therapy, and surgery, can pose financial barriers to patients seeking optimal care. High out-of-pocket expenses and limited insurance coverage may lead to treatment delays or inadequate adherence to prescribed therapies.

• Resistance to Current Therapies: Despite advancements in targeted therapies and immunotherapy, resistance mechanisms may develop over time, limiting the efficacy of existing treatments and necessitating the development of alternative therapeutic approaches. Acquired resistance to chemotherapy agents and molecularly targeted drugs poses challenges in managing advanced colorectal cancer.

• Limited Screening Uptake: Suboptimal uptake of colorectal cancer screening among eligible individuals contributes to late-stage diagnoses and missed opportunities for early intervention. Factors such as lack of awareness, reluctance to undergo invasive procedures like colonoscopy, and fear of receiving a cancer diagnosis contribute to low screening rates, hindering efforts to reduce mortality and morbidity associated with the disease.

• Emerging Infectious Diseases: Outbreaks of infectious diseases, such as the COVID-19 pandemic, disrupt healthcare systems, divert resources away from cancer care, and lead to delays in cancer screenings, diagnostic procedures, and treatment initiation. These disruptions may exacerbate existing disparities in access to care and impede progress in colorectal cancer management and outcomes.

Category-Wise Insights

By Type of Treatment:

• Surgery: Surgical removal of colorectal tumors is a cornerstone of treatment. Minimally invasive techniques like laparoscopic and robotic-assisted surgery are increasingly adopted, reducing recovery times. Enhanced recovery programs and organ preservation strategies are emerging trends, aiming to improve patient outcomes and quality of life.

• Chemotherapy: Chemotherapy involves the use of drugs to kill cancer cells. Trends in the colorectal cancer market include the development of novel chemotherapy regimens with improved efficacy and reduced toxicity, as well as the integration of targeted therapies and immunotherapy agents into chemotherapy-based treatment approaches.

• Radiation Therapy: Radiation therapy utilizes high-energy beams to destroy cancer cells. Advancements in radiation delivery techniques, such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT), allow for more precise tumor targeting and reduced toxicity to surrounding healthy tissues. Additionally, ongoing research explores the role of radiation therapy in combination with other treatment modalities.

• Targeted Therapy: Targeted therapies specifically target molecular pathways involved in colorectal cancer growth and progression. Trends in this segment include the development of targeted drugs against specific mutations such as KRAS, BRAF, and HER2, as well as the exploration of combination therapies targeting multiple pathways to overcome resistance mechanisms.

• Immunotherapy: Immunotherapy harnesses the body’s immune system to fight cancer. Key trends in the colorectal cancer market include the approval of immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 pathways for advanced colorectal cancer, as well as ongoing research into biomarkers predictive of immunotherapy response and combination strategies with other treatment modalities.

• Combination Therapies: Combination therapies involve the use of multiple treatment modalities simultaneously or sequentially to maximize efficacy and overcome resistance. Emerging trends in the colorectal cancer market include the investigation of combination regimens incorporating chemotherapy, targeted therapy, immunotherapy, and radiation therapy, guided by molecular profiling and patient-specific characteristics.

By Molecular Characteristics

• Microsatellite stable (MSS): Colorectal cancer with stable microsatellites, indicating genomic stability. Trends include focus on chemotherapy and targeted therapies due to limited immunotherapy efficacy.

• Microsatellite instability-high (MSI-H): Colorectal cancer with high microsatellite instability, indicating DNA repair deficiency. Trends include increasing adoption of immunotherapy, biomarker testing, and clinical trials targeting MSI-H tumors.

• RAS mutation status (KRAS, NRAS): Colorectal cancer with mutations in RAS genes, affecting signaling pathways. Trends include the development of targeted therapies and combination treatments to overcome resistance and improve outcomes for RAS-mutated tumors.

• BRAF mutation status: Colorectal cancer with mutations in the BRAF gene, affecting cell growth regulation. Trends include targeted therapies and combination treatments to address BRAF-mutated tumors, as well as biomarker-driven clinical trials for precision medicine approaches.

• HER2 status: Colorectal cancer with overexpression or amplification of HER2 protein. Trends include the investigation of HER2-targeted therapies, such as monoclonal antibodies and antibody-drug conjugates, as potential treatments for HER2-positive colorectal tumors.

By Route of Administration

• Oral: Oral administration in the colorectal cancer market involves delivering medications via the mouth, typically in the form of pills or capsules. Trends include the development of oral chemotherapy agents and targeted therapies, offering convenience and flexibility to patients, as well as advancements in oral delivery technologies to enhance drug absorption and efficacy.

• Parenteral: Parenteral administration involves delivering medications directly into the bloodstream, bypassing the digestive system. In colorectal cancer treatment, parenteral routes include intravenous and subcutaneous injections. Trends include the development of intravenous chemotherapy regimens, targeted biologics, and immunotherapies, aiming to improve treatment outcomes and reduce systemic side effects.

• Others: Other routes of administration in the colorectal cancer market may include rectal, transdermal, or intraperitoneal delivery methods. Rectal administration may involve suppositories or enemas for localized treatment, while transdermal patches and intraperitoneal chemotherapy offer alternative routes for drug delivery.

By Distribution Channel

• Hospital Pharmacy: Hospital pharmacies dispense medications to patients receiving inpatient or outpatient care within hospital settings. Trends include the integration of precision medicine approaches, expansion of formulary options for targeted therapies, and increased adoption of specialty pharmacy services for the management of colorectal cancer.

• Online Pharmacy: Online pharmacies facilitate the purchase and delivery of medications via internet-based platforms. Trends include the growing popularity of telehealth services for medication consultations and prescription refills, increased availability of specialty oncology medications, and adherence support programs tailored to colorectal cancer patients.

• Retail Pharmacy: Retail pharmacies provide prescription and over-the-counter medications, as well as health-related products, to consumers through brick-and-mortar locations. Trends include the expansion of pharmacist-led medication therapy management services, increased accessibility to colorectal cancer screening kits and preventive medications, and patient education initiatives focused on cancer prevention and management.

• Others: This category may include specialty pharmacies, compounding pharmacies, or unconventional distribution channels for medications and medical supplies. Trends may involve the emergence of innovative drug delivery methods, such as implantable devices or targeted drug delivery systems, tailored to the needs of colorectal cancer patients.

Report Scope

Colorectal Cancer Market – Regional Analysis

The Colorectal Cancer Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

• North America: In North America, trends in the colorectal cancer market include the widespread adoption of advanced screening techniques such as colonoscopies and faecal immunochemical tests (FIT), increased utilization of targeted therapies and immunotherapy in treatment regimens, and emphasis on precision medicine approaches for patient stratification and personalized treatment plans.

• Europe: In Europe, trends in the colorectal cancer market encompass efforts to improve screening participation rates through organized screening programs and public awareness campaigns, expansion of multidisciplinary care teams to optimize treatment outcomes, and implementation of value-based healthcare models to ensure cost-effective delivery of colorectal cancer services.

• Asia-Pacific: In the Asia-Pacific region, trends in the colorectal cancer market include rising incidence rates due to lifestyle changes and population aging, adoption of innovative diagnostic technologies such as liquid biopsies and molecular profiling assays, and expansion of access to affordable treatment options through government-sponsored healthcare initiatives and collaborations with international organizations.

• LAMEA: In the LAMEA (Latin America, Middle East, and Africa) region, trends in the colorectal cancer market encompass efforts to address disparities in healthcare access and quality of care through infrastructure development and capacity-building initiatives, increasing emphasis on early detection and screening programs, and integration of palliative care services to improve quality of life for patients with advanced disease.

Competitive Landscape – Colorectal Cancer Market

The Colorectal Cancer Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

• Hoffmann-La Roche Ltd
• Merck & Co. Inc.
• Bayer AG
• Amgen Inc.
• Bristol Myers Squibb Company
• Eli Lilly and Company
• Novartis International AG
• AstraZeneca PLC
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• Daiichi Sankyo Company Limited
• Johnson & Johnson
• Others

These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.

Several new players entering the colorectal cancer market are adopting innovation and development strategies to establish their presence. These players often focus on niche areas such as precision medicine, biomarker discovery, or novel drug delivery systems to differentiate themselves.

Key players dominating the market, including F. Hoffmann-La Roche Ltd, Merck & Co., Inc., and Bayer AG, maintain their dominance through extensive R&D investments, robust product pipelines, established distribution networks, and strategic partnerships. They leverage their market experience and brand recognition to drive the adoption of their therapies and maintain a competitive advantage.

The Colorectal Cancer Market is segmented as follows:

By Type of Treatment

• Surgery
• Chemotherapy
• Radiation Therapy
• Targeted Therapy
• Immunotherapy
• Combination therapies

By Molecular Characteristics

• Microsatellite stable (MSS)
• Microsatellite instability-high (MSI-H)
• RAS mutation status (KRAS, NRAS)
• BRAF mutation status
• HER2 status

By Route of Administration

• Oral
• Parenteral
• Others

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America